Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Migraine

Research output: Contribution to journalReviewResearchpeer-review

  1. Wilms tumour

    Research output: Contribution to journalReviewResearchpeer-review

  2. Tension-type headache

    Research output: Contribution to journalReviewResearchpeer-review

  3. Motile ciliopathies

    Research output: Contribution to journalReviewResearchpeer-review

  4. Gestational diabetes mellitus

    Research output: Contribution to journalReviewResearchpeer-review

  5. Testicular cancer

    Research output: Contribution to journalReviewResearchpeer-review

  1. Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment

    Research output: Contribution to journalReviewResearchpeer-review

  2. Human Cerebral Perfusion, Oxygen Consumption, and Lactate Production in Response to Hypoxic Exposure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Brain barriers and their potential role in migraine pathophysiology

    Research output: Contribution to journalReviewResearchpeer-review

  4. Migraine and light: A narrative review

    Research output: Contribution to journalReviewResearchpeer-review

  • Michel D Ferrari
  • Peter J Goadsby
  • Rami Burstein
  • Tobias Kurth
  • Cenk Ayata
  • Andrew Charles
  • Messoud Ashina
  • Arn M J M van den Maagdenberg
  • David W Dodick
View graph of relations

Migraine is a common, chronic, disorder that is typically characterized by recurrent disabling attacks of headache and accompanying symptoms, including aura. The aetiology is multifactorial with rare monogenic variants. Depression, epilepsy, stroke and myocardial infarction are comorbid diseases. Spreading depolarization probably causes aura and possibly also triggers trigeminal sensory activation, the underlying mechanism for the headache. Despite earlier beliefs, vasodilation is only a secondary phenomenon and vasoconstriction is not essential for antimigraine efficacy. Management includes analgesics or NSAIDs for mild attacks, and, for moderate or severe attacks, triptans or 5HT1B/1D receptor agonists. Because of cardiovascular safety concerns, unreliable efficacy and tolerability issues, use of ergots to abort attacks has nearly vanished in most countries. CGRP receptor antagonists (gepants) and lasmiditan, a selective 5HT1F receptor agonist, have emerged as effective acute treatments. Intramuscular onabotulinumtoxinA may be helpful in chronic migraine (migraine on ≥15 days per month) and monoclonal antibodies targeting CGRP or its receptor, as well as two gepants, have proven effective and well tolerated for the preventive treatment of migraine. Several neuromodulation modalities have been approved for acute and/or preventive migraine treatment. The emergence of new treatment targets and therapies illustrates the bright future for migraine management.

Original languageEnglish
Article number2
JournalNature reviews. Disease primers
Volume8
Issue number1
Pages (from-to)2
ISSN2056-676X
DOIs
Publication statusPublished - 2022

Bibliographical note

© 2022. Springer Nature Limited.

ID: 72159848